Swiss National Bank Purchases 4,200 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Swiss National Bank raised its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 1.8% during the fourth quarter, HoldingsChannel reports. The fund owned 235,900 shares of the biopharmaceutical company’s stock after acquiring an additional 4,200 shares during the quarter. Swiss National Bank’s holdings in Catalyst Pharmaceuticals were worth $4,388,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $31,000. FMR LLC grew its holdings in shares of Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares during the last quarter. Covestor Ltd grew its holdings in shares of Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,316 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Catalyst Pharmaceuticals in the first quarter worth about $62,000. Finally, Convergence Investment Partners LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $148,000. Institutional investors own 86.66% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany sold 26,151 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $13.23, for a total transaction of $345,977.73. Following the completion of the sale, the chief executive officer now directly owns 3,945,436 shares of the company’s stock, valued at $52,198,118.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Brian Elsbernd sold 50,000 shares of the company’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $16.07, for a total transaction of $803,500.00. Following the transaction, the insider now owns 138,076 shares in the company, valued at $2,218,881.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Patrick J. Mcenany sold 26,151 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $13.23, for a total transaction of $345,977.73. Following the transaction, the chief executive officer now owns 3,945,436 shares in the company, valued at approximately $52,198,118.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 246,151 shares of company stock valued at $3,974,706. 14.10% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $12.17 on Friday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $6.15 and a 1-year high of $22.11. The company has a 50-day moving average of $16.11 and a 200 day moving average of $16.51. The firm has a market cap of $1.29 billion, a PE ratio of 13.83 and a beta of 1.11.

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) last released its quarterly earnings data on Wednesday, March 15th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. Catalyst Pharmaceuticals had a net margin of 38.76% and a return on equity of 34.72%. The company had revenue of $60.76 million during the quarter, compared to analyst estimates of $60.64 million. Sell-side analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on CPRX. Cantor Fitzgerald upped their price target on shares of Catalyst Pharmaceuticals from $22.00 to $25.00 in a report on Friday, March 17th. StockNews.com cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, May 15th. Finally, Piper Sandler upped their price target on shares of Catalyst Pharmaceuticals from $20.00 to $21.00 in a report on Tuesday, February 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.50.

About Catalyst Pharmaceuticals

(Get Rating)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.